As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
Similar Posts
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors
As with any medicine, the MHRA will keep the safety and effectiveness of concizumab under close review.
National assessment procedure for medicines
Guidance on the MHRA’s national assessment procedure for marketing authorisation applications.
Clinical trials for medicines: apply for authorisation in the UK
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
MHRA Chair welcomes re-appointment of three non-executive directors
Professor Anthony Harnden has congratulated the trio of Agency board members on the extension of their appointments.
Guidance: AI Airlock Simulation Workshops
Key insights of three simulation workshops from the AI Airlock pilot testing programme. Please note that these documents are not formal guidance.
MHRA Safety Roundup: February 2026
Summary of the latest safety advice for medicines and medical device users